GlassScriptPhysician profile
Brett Welch
NPI 1386172856
$1,433.18
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $332 · 2022: $328 · 2023: $410 · 2024: $364.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $774.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $773.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $399.26 | 2021-2024 | |
| Janssen Pharmaceuticals, INC | $255.47 | 2021-2022 | |
| Pfizer INC. | $226.54 | 2021-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $139.79 | 2022-2024 | Jardiance |
| Amgen INC. | $129.10 | 2021-2023 | Repatha |
| Astrazeneca Pharmaceuticals LP | $68.67 | 2021-2024 | Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $49.75 | 2024 | |
| Amarin Pharma, INC. | $21.74 | 2021 | |
| Kiniksa Pharmaceuticals International, Plc | $19.82 | 2024 | Arcalyst |
| Novo Nordisk INC | $18.91 | 2021 | |
| Alnylam Pharmaceuticals INC. | $18.49 | 2023 | Onpattro |
| Chiesi USA, INC. | $16.42 | 2023 | Kengreal |
| Impulse Dynamics (USA) INC. | $16.19 | 2024 | Optimizer |
| Scpharmaceuticals INC. | $15.75 | 2024 | |
| Merck Sharp & Dohme LLC | $15.70 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $11.21 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $10.37 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brett Welch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.